Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun;263(2):242-256.
doi: 10.1002/path.6280. Epub 2024 Apr 5.

Co-targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor-null prostate cancer

Nicholas Choo  1 , Shivakumar Keerthikumar  1   2   3 , Susanne Ramm  3   4 , Daisaku Ashikari  1 , Linda Teng  1 , Birunthi Niranjan  1 , Shelley Hedwards  1 , Laura H Porter  1 , David L Goode  2   3   5 , Kaylene J Simpson  3   4   6 , Renea A Taylor  2   3   7   8 , Gail P Risbridger  1   2   3   8 , Mitchell G Lawrence  1   2   3   8
Affiliations

Co-targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor-null prostate cancer

Nicholas Choo et al. J Pathol. 2024 Jun.

Abstract

There are diverse phenotypes of castration-resistant prostate cancer, including neuroendocrine disease, that vary in their sensitivity to drug treatment. The efficacy of BET and CBP/p300 inhibitors in prostate cancer is attributed, at least in part, to their ability to decrease androgen receptor (AR) signalling. However, the activity of BET and CBP/p300 inhibitors in prostate cancers that lack the AR is unclear. In this study, we showed that BRD4, CBP, and p300 were co-expressed in AR-positive and AR-null prostate cancer. A combined inhibitor of these three proteins, NEO2734, reduced the growth of both AR-positive and AR-null organoids, as measured by changes in viability, size, and composition. NEO2734 treatment caused consistent transcriptional downregulation of cell cycle pathways. In neuroendocrine models, NEO2734 treatment reduced ASCL1 levels and other neuroendocrine markers, and reduced tumour growth in vivo. Collectively, these results show that epigenome-targeted inhibitors cause decreased growth and phenotype-dependent disruption of lineage regulators in neuroendocrine prostate cancer, warranting further development of compounds with this activity in the clinic. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Keywords: BRD4; CBP/p300; NEO2734; PDX; neuroendocrine; organoids; prostate cancer.

PubMed Disclaimer

References

    1. Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011; 1: 487–495.
    1. Zaffuto E, Pompe R, Zanaty M, et al. Contemporary incidence and cancer control outcomes of primary neuroendocrine prostate cancer: a SEER database analysis. Clin Genitourin Cancer 2017; 15: e793–e800.
    1. Beltran H, Prandi D, Mosquera JM, et al. Divergent clonal evolution of castration‐resistant neuroendocrine prostate cancer. Nat Med 2016; 22: 298–305.
    1. Bluemn EG, Coleman IM, Lucas JM, et al. Androgen receptor pathway‐independent prostate cancer is sustained through FGF Signaling. Cancer Cell 2017; 32: 474–489.e6.
    1. Nouruzi S, Ganguli D, Tabrizian N, et al. ASCL1 activates neuronal stem cell‐like lineage programming through remodeling of the chromatin landscape in prostate cancer. Nat Commun 2022; 13: 2282.

Publication types

MeSH terms